Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

[1]  R. Advani,et al.  Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. , 2015, Blood.

[2]  R. Advani,et al.  Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes , 2015, Leukemia.

[3]  Amy P Abernethy,et al.  Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). , 2014, Journal of the National Cancer Institute.

[4]  G. Salles,et al.  PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. , 2014, The New England journal of medicine.

[5]  R. Houot,et al.  A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma , 2013, Clinical Cancer Research.

[6]  Y. Chu,et al.  Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia. , 2013, Future oncology.

[7]  Scott E Smith,et al.  Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Friedberg.  Relapsed/refractory diffuse large B-cell lymphoma. , 2011, Hematology. American Society of Hematology. Education Program.

[9]  John P Leonard,et al.  Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. , 2010, The New England journal of medicine.

[10]  E. Kimby,et al.  Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Giné,et al.  Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Jeffrey T. Lau,et al.  Therapeutic potential of an anti-CD79b antibody-drug conjugate, anti-CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. , 2009, Blood.

[13]  R. Gascoyne,et al.  Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma , 2009, Cancer.

[14]  G. Frantz,et al.  Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection. , 2009, Cancer research.

[15]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[16]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Thomas J. Smith,et al.  2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Czuczman,et al.  A Quantitative Exploration of Surface Antigen Expression in Common B-Cell Malignancies Using Flow Cytometry , 2006, Immunological investigations.

[19]  Damon L. Meyer,et al.  cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. , 2003, Blood.

[20]  Damon L. Meyer,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003, Nature Biotechnology.

[21]  P. Musto,et al.  Quantitative flow cytometry for the differential diagnosis of leukemic B‐cell chronic lymphoproliferative disorders , 2000, American journal of hematology.

[22]  E. Hamel,et al.  Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. , 1990, The Journal of biological chemistry.

[23]  E. Matutes,et al.  Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. , 1999, Haematologica.